Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF Wild-Type Anaplastic Thyroid Carcinoma.

Thyroid : official journal of the American Thyroid Association - 1 Feb 2026

Hamidi Sarah, Vodopivec Danica M, Busaidy Naifa L, Gule-Monroe Maria, Akhave Neal S, Banuchi Victoria E, Ferraroto Renata, Fournier Isabelle, Gunn G Brandon, Iyer Priyanka C, Lee Anna, Maniakas Anastasios, Marczyk Vicente R, Ning Matthew S, Sousa Luana G, Spiotto Micheal T, Waguespack Steven G, Wang Jennifer R, Zafereo Mark E, Cabanillas Maria E, Dadu Ramona

Abstract excerpt

INTRODUCTION: BRAF wild-type anaplastic thyroid carcinomas (BRAFWT-ATCs) have a poor prognosis, in part, due to limited effective therapies. The preliminary results from the phase II ATLEP trial suggest the promising clinical activity of lenvatinib plus pembrolizumab (L/P). We aimed to confirm the real-world efficacy of L/P in BRAFWT-ATC. METHODS: A retrospective single-center study of patients with BRAFWT-ATC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Neoplasm Metastasis

Share to Phenylurea Compounds

Share to Progression-Free Survival

Share to Quinolines

Share to Thyroid Carcinoma, Anaplastic

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 41791883
DOI: 10.1177/10507256251409138

Genes

BRAF
NF1
TERT
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF Wild-Type Anaplastic Thyroid Carcinoma.PMID 41791883Read ↗

Recent advances in anaplastic thyroid cancer management.Semantic proximity Read ↗

Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.Semantic proximity Read ↗

Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.Semantic proximity Read ↗

Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.Semantic proximity Read ↗

Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report.Semantic proximity Read ↗

Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic.Semantic proximity Read ↗

Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.Semantic proximity Read ↗

Current picture of anaplastic thyroid cancer patients' care and meetable needs: A survey of 94 Institutions from the EORTC Endocrine and Head and Neck Cancer Groups.Semantic proximity Read ↗

Promising Therapeutic Targets for Recurrent/Metastatic Anaplastic Thyroid Cancer.Semantic proximity Read ↗

A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancerSemantic proximity Read ↗

Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.Semantic proximity Read ↗

Advances in targeted therapy for anaplastic thyroid carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.